Abstract: Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.

Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: Provided herein are compositions and methods for co-production and recovery of two or more isoprenoids from a single recombinant cell.

Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Abstract: The invention includes an orally ingestible delivery system for releasing a therapeutic agent within an intestine of a mammal, where the system includes the therapeutic agent and a differentially permeable capsule system containing the therapeutic agent within a therapeutic agent compartment, with the differentially permeable capsule system dimensionally adapted for oral ingestion and for passage into a stomach of the mammal and thence into the intestine, wherein the differentially permeable capsule system comprises an acid-resistant shell and a dispersible acid barrier, wherein the dispersible acid barrier forms while the orally-ingestible delivery system is in the stomach; and wherein the dispersible acid barrier is dispersed in the intestine, thereby permitting enzymes in the intestine to reach the therapeutic agent compartment. The invention also includes methods of manufacturing the system and methods for its use.

Abstract: The present invention provides a Streptomyces sp. SNC087 strain (KCCM12505P) that is isolated from seawater and produces staurosporine, a method for producing staurosporine using the same, a method for culturing the same, and a pure culture medium of the same.

Abstract: The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.

Abstract: A formulation for stabilizing soils is described comprising bacteria, enzymes and cations, wherein the bacteria preferably correspond to Azotobacter vinelandii and Acidithiobacillus ferrooxidans, the enzyme preferably corresponds to an alginase and the cations are preferably provided in the form of calcium chloride. A method for stabilizing soils; a method for preparing stabilized paths; and use of the soil-stabilizing composition are also described.

Abstract: Recombinant Aspergillus genetically modified to increase expression of g8846, renamed herein as aconitic acid exporter (aexA), are provided, which in some examples are also genetically inactivated for an endogenous cis-aconitic acid decarboxylase (cadA) gene. Such recombinant Aspergillus produce more aconitic acid as compared to native Aspergillus. Also provided are methods of using such recombinant Aspergillus to increase production of aconitic acid and other organic acids, such as citric acid, itaconic acid, and 3-hydroxypropionic acid (3-HP).

Abstract: Disclosed are biomaterials, including engineered living materials (ELMs), comprising a plurality of microbial cells, wherein the material has a Young's Modulus of at least 5 Gpa; and methods of fabricating said biomaterials.

Abstract: Provided is a Lactiplantibacillus plantarum TCI837, deposited in the Leibniz Institute DSMZ under an accession number of DSM 33843. Based on this, the Lactiplantibacillis plantarum TCI837 can be used to prepare a composition for supplementing iron and/or promoting the absorption of iron in a subject, and to prepare a composition for improving the gut microbiota in a subject. In addition, the composition may be an iron supplement composition containing the Lactiplantibacillus plantarum TCI837 and an iron supplement.

Abstract: Provided herein are methods and systems for analysis of one or more single cells. The disclosed methods may comprise barcoding analytes from cell types of interest, while eliminating undesired cell types from analysis. Barcoding may comprise the use of a targeting agent. A targeting agent may be attached to an inhibitor or an activator, thereby inhibiting or activating analyte barcoding.

Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Abstract: The present invention relates to novel stable bacterial extract preparations having substantial increased stability over time, novel methods of preparation thereof, pharmaceutical formulations based on these novel stabilized bacterial extracts, as well as novel routes of administration and delivery devices for treating and/or preventing acute and chronic immunological disorders resulting from infections and/or inflammation and/or neoplasms and/or dysbiosis.

Abstract: Compositions and methods for converting at least one glucosinolate to an isothiocyanate using Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and/or Pediococcus pentosaceus M2_H12, or active variants thereof, are provided. Conversion of glucosinolates, such as glucoraphanin, to isothiocyanates, such as sulforaphane, leads to the stimulation of the Nrf2/Keap pathway and phase II enzymes, providing chemoprotective and anti-inflammatory effects. Accordingly, provided herein are compositions comprising Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and/or Pediococcus pentosaceus M2_H12, or active variants thereof, for administration to subjects for increasing isothiocyanate (e.g., sulforaphane) production, increasing the expression of genes regulated by the Nrf2 transcription factor, including phase II enzymes, decreasing inflammation, and treating or preventing an inflammatory disorder or a cancer.

Abstract: Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.

Abstract: The present disclosure illustrates an apparatus (100) and method (400) for detection of proteolytic activity of an enzyme and for assessing the level of matrix metalloproteinases in a biological sample. The apparatus (100) comprises a tubular outer jacket (109) with a seal cap (107). The apparatus (100) comprises one or more inner segment tubes (101, 103, 105) connected to each other at a lower end opening of each of the one or more tubes. The one or more inner segment tubes (101, 103, 105) comprises at least two chambers separated by a protein substrate layer (102, 104, 106). The level of the matrix metalloproteinases is assessed on the basis of number of protein layers digested and the proteolytic activity level of by the biological sample.

Abstract: The present invention is related to a method of reducing tobacco addiction in a smoking subject with Lactobacillus fermentum GKF3, including daily administering an oral composition containing the Lactobacillus fermentum GKF3 to the smoking subject, in which the oral composition reduces the total amount of the nicotine metabolites in urine.

Abstract: A mutant strain of Trichoderma reesei has a mutation that eliminates or reduces a function of a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 2. A method produces a protein, the method including a step of cultivating the mutant strain.